Kolte Patil Dev. (KOLTEPATIL)

Cyclical

FairStock Score: 29/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Current Price₹477.7
Market Cap₹4,236.25 Cr
P/E Ratio81.24
ROCE10.87%
ROE3.47%
Dividend Yield0%
Profit Growth-82.21%
Debt/Equity0.98
Sales Growth1,016.5%
Promoter Holding73.81%
52-Week Range₹292.25 — ₹554.6
SectorRealty
Book Value₹136.1

Strengths

Concerns

AI Analysis

Whenever I see a real estate company, I remind myself that land is not a moat and bricks do not compound. Kolte Patil Dev. currently sells at ₹390.65 with a market cap of ₹3,145 Cr. That is 4.67 times book value of ₹83.58 and 74.24 times trailing earnings. But those earnings are collapsing: profit is down 82.21% and sales are down 24.12%. In the latest quarter, sales were ₹265 Cr but net profit was only ₹4 Cr. That is roughly a 1.5% net margin. As Graham would say, price is what you pay, value is what you get. I do not see value here. Return on equity is 3.47%, far below what a quality business should earn, and even ROCE of 10.87% is mediocre. Debt/equity of 0.86 is not disastrous, but the Piotroski F-score of 3/9 tells me financial health is weak. With zero dividend, the shareholder depends entirely on price appreciation, and at this valuation, hope is not an investment strategy. Promoter holding of 73.81% is good, but high ownership does not replace profitability. This looks like a cyclical business under stress, not a franchise with pricing power. In real estate, today's cheap-looking P/E can become tomorrow's expensive one when earnings fall further. I would need evidence of sales recovering, margins rebuilding, and debt staying controlled before I could even consider a margin of safety. A FairStock score of 0/100 agrees. This is not a wonderful business at a fair price; it is a challenged business at an uncertain price. For the Indian retail investor, patience is better than a P/E of 74 in a downturn.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer